Trial Profile
Phase I Study of the Combination of Apatinib and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms SYLT 007 study
- 13 Sep 2022 Results (data cutoff date: 30 Mar 2022) after two additional years of follow-up presented at the 47th European Society for Medical Oncology Congress
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 24 Jan 2018 Planned number of patients changed from 9 to 18.